
Acadia cancels development of intranasal carbetocin in rare disease
Acadia Pharmaceuticals has announced that its Phase III COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS) did not meet its primary endpoint. The treatment did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from… Read More
